What are the evidence‑based lifestyle and pharmacologic recommendations for managing hypertension in adults?

Hypertension Management in Adults

Blood Pressure Classification and Treatment Thresholds

For adults with blood pressure ≥130/80 mmHg who have cardiovascular risk factors (age ≥65 years, diabetes, chronic kidney disease, or established cardiovascular disease), initiate pharmacologic therapy immediately together with lifestyle modifications—delaying treatment for lifestyle changes alone is inappropriate. 1

• Blood pressure should be categorized as normal (<120/80 mmHg), elevated (120-129/<80 mmHg), stage 1 hypertension (130-139/80-89 mmHg), or stage 2 hypertension (≥140/90 mmHg). 2
• Stage 2 hypertension (≥140/90 mmHg) warrants immediate initiation of two antihypertensive agents or a single-pill combination, together with lifestyle therapy. 3
• The minimum treatment goal is <140/90 mmHg, with an optimal target of <130/80 mmHg for most adults; for those aged ≥65 years, aim for systolic 130-139 mmHg. 1, 4

Lifestyle Modifications (Implemented Simultaneously with Pharmacotherapy)

Comprehensive lifestyle interventions can lower systolic/diastolic blood pressure by 10-20 mmHg and must be initiated concurrently with medications, not as a delay tactic. 2, 3

Dietary Interventions

• Restrict sodium intake to <2 g/day (approximately 5 g salt), which yields a 5-10 mmHg systolic reduction and enhances the efficacy of all antihypertensive classes, especially diuretics and renin-angiotensin system blockers. 3, 1
• Adopt the DASH dietary pattern (8-10 servings of fruits/vegetables daily, 2-3 servings of low-fat dairy, whole grains, limited saturated fat <7% of total calories), which reduces blood pressure by approximately 11.4/5.5 mmHg. 3, 1
• Increase potassium intake through fruits, vegetables, and low-fat dairy unless contraindicated by advanced kidney disease or potassium-sparing medications. 1, 5

Physical Activity and Weight Management

• Perform at least 150 minutes/week of moderate-intensity aerobic activity (or 75 minutes/week of vigorous activity), which lowers blood pressure by approximately 4/3 mmHg. 3, 1
• Add resistance training 2-3 times per week. 1
• Weight reduction in overweight/obese patients: each 10 kg loss decreases blood pressure by approximately 6.0/4.6 mmHg. 3, 1

Alcohol and Tobacco

• Limit alcohol to ≤2 drinks/day for men and ≤1 drink/day for women. 3, 1
• Complete smoking cessation is mandatory, as continued smoking outweighs the benefit of blood pressure control. 1

First-Line Pharmacologic Therapy

Begin with a two-drug fixed-dose combination that includes a renin-angiotensin system blocker (ACE inhibitor or ARB) plus either a dihydropyridine calcium-channel blocker (preferred) or a thiazide-like diuretic (chlorthalidone or indapamide). 1, 6

Initial Combination Therapy Selection

• For non-Black patients without compelling indications, start with an ACE inhibitor or ARB combined with a calcium-channel blocker or thiazide-like diuretic. 2, 7
• For Black patients, a calcium-channel blocker or thiazide-type diuretic is recommended as initial therapy; the combination of calcium-channel blocker plus thiazide diuretic may be more effective than calcium-channel blocker plus ACE inhibitor/ARB. 3, 8
• Fixed-dose single-pill combinations should be used when available to improve medication adherence and persistence. 3, 1

Compelling Indications for Specific Agents

• Diabetes with albuminuria (UACR ≥30 mg/g): ACE inhibitor or ARB is required to slow kidney disease progression. 1, 5
• Established coronary artery disease: ACE inhibitor or ARB is strongly recommended as first-line therapy. 1, 6
• Chronic kidney disease with proteinuria: A renin-angiotensin system blocker (ACE inhibitor or ARB) is essential. 1, 8
• Heart failure with reduced ejection fraction or post-myocardial infarction: Beta-blockers and ACE inhibitors are recommended as first-line therapy. 3, 9

Treatment Escalation Algorithm

Step 1: Dual Therapy

• Start with renin-angiotensin system blocker plus calcium-channel blocker or renin-angiotensin system blocker plus thiazide-like diuretic (fixed-dose combination preferred). 1, 6
• Re-measure blood pressure 2-4 weeks after initiating therapy. 3, 4

Step 2: Triple Therapy

• If blood pressure is not at target after 2-4 weeks on dual therapy, add a third agent to create the combination: renin-angiotensin system blocker plus calcium-channel blocker plus thiazide-like diuretic. 3, 1
• Chlorthalidone 12.5-25 mg daily is preferred over hydrochlorothiazide due to its longer duration of action and superior cardiovascular outcome data from the ALLHAT trial. 3

Step 3: Resistant Hypertension (Fourth-Line Agent)

• For blood pressure remaining ≥140/90 mmHg after optimized triple therapy, add spironolactone 25-50 mg daily as the preferred fourth-line agent, which produces additional reductions of approximately 20-25 mmHg systolic and 10-12 mmHg diastolic. 3, 1
• Monitor serum potassium and creatinine 2-4 weeks after initiating spironolactone because of increased hyperkalemia risk when combined with ACE inhibitor or ARB. 3, 1

Monitoring Requirements

Initial Follow-Up

• Check serum creatinine and potassium 7-14 days (or 1-2 weeks) after starting or adjusting an ACE inhibitor, ARB, or mineralocorticoid receptor antagonist. 1
• When a thiazide-type diuretic is introduced, check serum potassium and creatinine 2-4 weeks later to identify hypokalemia or renal impairment. 3
• Re-measure blood pressure 2-4 weeks after any therapy initiation or dose change, with the goal of achieving target blood pressure within 3 months. 3, 1

Long-Term Monitoring

• Once blood pressure is controlled, schedule visits every 3-6 months; perform an annual reassessment of blood pressure and cardiovascular risk factors. 1

Critical Pitfalls to Avoid

Medication Selection Errors

• Do not combine two renin-angiotensin system blockers (ACE inhibitor plus ARB), as dual blockade increases the risk of hyperkalemia, acute kidney injury, and hypotension without added cardiovascular benefit. 3, 1, 6
• Do not add a beta-blocker as second or third-line agent unless there are compelling indications (angina, post-myocardial infarction, heart failure with reduced ejection fraction, atrial fibrillation requiring rate control), because beta-blockers are less effective than calcium-channel blockers or thiazide diuretics for stroke prevention and cardiovascular event reduction in uncomplicated hypertension. 3, 1
• Do not use non-dihydropyridine calcium-channel blockers (diltiazem, verapamil) in patients with heart failure because of their negative inotropic effects. 3

Treatment Approach Errors

• Do not use monotherapy when blood pressure is ≥140/90 mmHg or ≥130/80 mmHg with high-risk features; combination therapy is more effective and reaches blood pressure goals faster. 1, 6
• Do not delay treatment intensification when blood pressure remains ≥140/90 mmHg; prompt action within 2-4 weeks is required to reduce cardiovascular risk. 3, 1
• Do not assume treatment failure without first confirming medication adherence (via pill counts, pharmacy refill data, or direct questioning), as non-adherence is the most common cause of apparent treatment resistance. 3, 1

Assessment Errors

• Do not postpone pharmacologic therapy in favor of lifestyle changes alone when blood pressure is ≥130/80 mmHg with cardiovascular risk factors; both must be initiated simultaneously. 1, 6
• Confirm true hypertension with home blood pressure monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) before escalating therapy to exclude white-coat hypertension. 3, 1
• Screen for secondary hypertension (primary aldosteronism, renal artery stenosis, obstructive sleep apnea, pheochromocytoma) when blood pressure is severely elevated (≥180/110 mmHg) or resistant to triple therapy. 3

Special Populations

Older Adults (≥65 Years)

• Target systolic blood pressure of 130-139 mmHg to balance benefit and safety; avoid diastolic <60 mmHg to prevent coronary hypoperfusion. 1, 4
• Maintain blood pressure-lowering medication indefinitely, even beyond age 85 years, if well tolerated. 6

Pregnancy

• ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists are contraindicated in pregnancy and should be avoided in women of child-bearing potential not using reliable contraception. 1